CXCL10 抗体 (Biotin)
-
- 抗原 See all CXCL10 抗体
- CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))
-
适用
- 人
-
宿主
- 山羊
-
克隆类型
- 多克隆
-
标记
- This CXCL10 antibody is conjugated to Biotin
-
应用范围
- Flow Cytometry (FACS)
- 纯化方法
- The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.
- 克隆位点
- Poly5194
- 亚型
- IgG
- Top Product
- Discover our top product CXCL10 Primary Antibody
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 浓度
- 0.5 mg/mL
- 缓冲液
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 注意事项
- Do not freeze.
- 储存条件
- 4 °C
- 储存方法
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- 抗原
- CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))
- 别名
- CXCL10 (CXCL10 产品)
- 背景
- CXCL10 is an ELR-negative chemokine structurally and functionally related to CXCL9 and CXCL11. CXCL10, CXCL9, and CXCL11 are produced and secreted by monocytes, macrophages, fibroblasts, and epithelial cells upon stimulation with proinflammatory cytokines, especially IFNγ. CXCL10 chemoattracts CD4, CD8, and NK and NKT cells through the binding to its receptor CXCR3, which is shared with CXCL9 and CXCL11. In addition, CXCL10 inhibits neovascularization in tumors and in wound healing in vivo. Also, CXCL10 has anti-proliferative effects on endothelial cells in vitro, and angiostatic and antitumor effects in vivo. It has been suggested that the anti-proliferative effect of CXCL10 in endothelial cells is CXCR3-independent and that it is mediated through GAG interaction. CXCL10 also possesses antimicrobial activity against E. coli and L. monocytogenes, and both the spore and bacillus forms of B. anthracis. CXCL10 expression is strongly upregulated in many human inflammatory diseases, including rheumatoid arthritis, type I diabetes, multiple sclerosis, atherosclerosis, allograft rejection, and others.
-